Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

Executive Summary

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.

Advertisement

Related Content

BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals
QIDP Roundup: Familiar Names Dominate 2019 Designations
Merck And The 'Strange Business' Of Antibiotics
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
Pharma Wakes Up To Transformative Progress In Hearing Loss Research
REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Resverlogix value decimated by RVX-208 failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125396

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel